Mr. Kamal was previously president of Prime Therapeutics and CEO of subsidiary MagellanRx.
Current CEO Ken Paulus plans to retire, according to a July 3 news release.
“Our newly combined organization has the right solutions, scale and know-how to be a powerful player in this market. I’m excited to lead the exceptionally talented teams that are making that vision a reality,” Mr. Kamal said in the release.
Prime Therapeutics, which is jointly owned by 19 Blue Cross Blue Shield companies, purchased MagellanRx from Centene in 2022.
